Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 20/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | HTR1B | P28222 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3909572 | 0.89 | HTR6 (0.70) | HTR6 | |
| SCHEMBL3912683 | 0.88 | HTR6 (0.77) | HTR6 | |
| SCHEMBL3919708 | 0.87 | HTR6 (0.71) | HTR6CYP1A2ADRB1CYP3A4HTR1A | |
| SCHEMBL3915879 | 0.87 | HTR6 (0.72) | HTR6HTR2CHTR3ASIGMAR1 | |
| SCHEMBL3910143 | 0.85 | HTR6 (0.72) | HTR6CYP1A2ADRB1CYP3A4 | |
| SCHEMBL3918119 | 0.83 | HTR6 (1.00) | HTR6 | |
| SCHEMBL3909167 | 0.80 | HTR6 (1.00) | HTR6HTR1ADRD2HTR1BHTR2C | |
| SCHEMBL3918674 | 0.80 | HTR6 (0.71) | HTR6CHRM1HTR2A | |
| Hydrochloric Acid SCHEMBL4079949 | 0.79 | HTR6 (0.98) | HTR6HTR1ADRD2HTR1BHTR2C | |
| SCHEMBL4082403 | 0.78 | HTR6 (0.71) | HTR6CYP1A2ADRB1CYP3A4HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501421-B2 | Benzoxazole and benzothiazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-03-10 | — | — | US | claimed |
| US-20070281945-A1 | Benzoxazole and benzothiazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-12-06 | — | — | US | claimed |
| US-7501421-B2 | Benzoxazole and benzothiazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-03-10 | — | — | US | disclosed |
| EP-2024348-A2 | BENZOXAZOLE AND BENZOTHIAZOLE DERIVATIVES AS 5-HYDROXYTRYTAMINE-6 LIGANDS | Wyeth (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007142904-A2 | BENZOXAZOLE AND BENZOTHIAZOLE DERIVATIVES AS 5-HYDROXYTRYTAMINE-6 LIGANDS | WYETH (US) | 2007-12-13 | — | — | WO | disclosed |
| US-20070281945-A1 | Benzoxazole and benzothiazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281945-A1 | Benzoxazole and benzothiazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR2C | HTR6 1/4885CYP1A2 433/4885ADRB1 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.